VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | The role of fedratinib in MF and the impact of this agent in the field

Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on the role of fedratinib in the treatment of myelofibrosis (MF), and further highlights the promising data that has emerged from recent clinical trials. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Disclosures

Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter